BR112019008675A2 - roedor, célula isolada de roedor, e, métodos de produção de um roedor e de um anticorpo em um roedor. - Google Patents
roedor, célula isolada de roedor, e, métodos de produção de um roedor e de um anticorpo em um roedor.Info
- Publication number
- BR112019008675A2 BR112019008675A2 BR112019008675A BR112019008675A BR112019008675A2 BR 112019008675 A2 BR112019008675 A2 BR 112019008675A2 BR 112019008675 A BR112019008675 A BR 112019008675A BR 112019008675 A BR112019008675 A BR 112019008675A BR 112019008675 A2 BR112019008675 A2 BR 112019008675A2
- Authority
- BR
- Brazil
- Prior art keywords
- rodent
- human
- methods
- human animals
- lambda light
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417845P | 2016-11-04 | 2016-11-04 | |
| US201762567932P | 2017-10-04 | 2017-10-04 | |
| PCT/US2017/060006 WO2018128691A1 (en) | 2016-11-04 | 2017-11-03 | Non-human animals having an engineered immunoglobulin lambda light chain locus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019008675A2 true BR112019008675A2 (pt) | 2019-07-09 |
Family
ID=62025924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019008675A BR112019008675A2 (pt) | 2016-11-04 | 2017-11-03 | roedor, célula isolada de roedor, e, métodos de produção de um roedor e de um anticorpo em um roedor. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10820582B2 (https=) |
| EP (4) | EP4082334B1 (https=) |
| JP (5) | JP6884860B2 (https=) |
| KR (4) | KR102492433B1 (https=) |
| CN (2) | CN109996441B (https=) |
| AU (2) | AU2017391167B2 (https=) |
| BR (1) | BR112019008675A2 (https=) |
| CA (1) | CA3038720A1 (https=) |
| CY (2) | CY1123491T1 (https=) |
| DK (3) | DK4082334T3 (https=) |
| ES (3) | ES2915609T3 (https=) |
| FI (1) | FI4082334T3 (https=) |
| HR (3) | HRP20201403T1 (https=) |
| HU (3) | HUE052087T2 (https=) |
| IL (2) | IL266282B2 (https=) |
| LT (3) | LT4082334T (https=) |
| MA (2) | MA53935A (https=) |
| MX (2) | MX385857B (https=) |
| PL (3) | PL4082334T3 (https=) |
| PT (3) | PT3766343T (https=) |
| RS (3) | RS63390B1 (https=) |
| RU (2) | RU2757665C2 (https=) |
| SG (2) | SG10201913483XA (https=) |
| SI (3) | SI4082334T1 (https=) |
| SM (3) | SMT202500204T1 (https=) |
| WO (1) | WO2018128691A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6482757B2 (ja) | 2010-07-26 | 2019-03-13 | トリアンニ インコーポレイテッドTrianni,Inc. | トランスジェニック動物および使用方法 |
| US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| RS62023B1 (sr) * | 2012-02-01 | 2021-07-30 | Regeneron Pharma | Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene |
| EP3384030A4 (en) | 2015-12-03 | 2019-07-03 | Trianni, Inc. | IMPROVED IMMUNOGLULINIVITY |
| WO2018128691A1 (en) | 2016-11-04 | 2018-07-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
| WO2019190922A1 (en) | 2018-03-24 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| KR20250121150A (ko) | 2018-03-26 | 2025-08-11 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| JP2022520819A (ja) | 2019-02-22 | 2022-04-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 遺伝子改変ナトリウムチャネルを有する齧歯類およびその使用方法 |
| WO2021003152A1 (en) * | 2019-07-01 | 2021-01-07 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| KR20230018439A (ko) * | 2020-06-02 | 2023-02-07 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물 |
| CA3187680A1 (en) | 2020-09-11 | 2022-03-17 | Yashu Liu | Identification and production of antigen-specific antibodies |
| WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| TW202242114A (zh) | 2020-12-23 | 2022-11-01 | 美商再生元醫藥公司 | 用於獲得結合至跨膜蛋白之抗體以及抗體生成細胞的方法 |
| IL312359A (en) * | 2021-11-10 | 2024-06-01 | Trianni Inc | Transgenic mammals and methods of use thereof |
| GB202217978D0 (en) * | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Rodents expressing a common light chain |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| WO2026035843A2 (en) | 2024-08-06 | 2026-02-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2124967C (en) * | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7435871B2 (en) | 2001-11-30 | 2008-10-14 | Amgen Fremont Inc. | Transgenic animals bearing human Igλ light chain genes |
| EP1644417B1 (en) * | 2003-07-15 | 2014-04-30 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| EP2346994B1 (en) | 2008-09-30 | 2022-02-16 | Ablexis, LLC | Knock-in mice for the production of chimeric antibodies |
| JP5827127B2 (ja) * | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
| BR112012000536A2 (pt) | 2009-07-08 | 2020-08-11 | Kymab Limited | métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| WO2011115476A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
| US9012717B2 (en) | 2010-06-22 | 2015-04-21 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
| RU2722373C2 (ru) | 2011-02-25 | 2020-05-29 | Редженерон Фармасьютикалс, Инк. | Мыши adam6 |
| KR20160098514A (ko) | 2011-10-17 | 2016-08-18 | 리제너론 파아마슈티컬스, 인크. | 제한된 면역글로불린 중쇄 마우스 |
| US9253965B2 (en) * | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| RU2664181C2 (ru) * | 2011-12-20 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Мыши с гуманизированной легкой цепью |
| EP2840892B1 (en) * | 2013-02-20 | 2018-04-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
| MX2015010841A (es) | 2013-02-20 | 2016-05-09 | Regeneron Pharma | Modificacion genetica de ratas. |
| US9788534B2 (en) * | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| DE112014004537T5 (de) * | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
| US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
| RS60359B1 (sr) | 2014-06-06 | 2020-07-31 | Regeneron Pharma | Postupci i kompozicije za modifikovanje ciljanog lokusa |
| HUE049405T2 (hu) | 2014-06-23 | 2020-09-28 | Regeneron Pharma | Nukleáz-közvetített DNS-összeállítás |
| ES2731437T3 (es) | 2014-11-21 | 2019-11-15 | Regeneron Pharma | Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías |
| KR102530821B1 (ko) | 2014-12-19 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물 |
| WO2018128691A1 (en) | 2016-11-04 | 2018-07-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
-
2017
- 2017-11-03 WO PCT/US2017/060006 patent/WO2018128691A1/en not_active Ceased
- 2017-11-03 PT PT201805082T patent/PT3766343T/pt unknown
- 2017-11-03 EP EP22164751.4A patent/EP4082334B1/en active Active
- 2017-11-03 IL IL266282A patent/IL266282B2/en unknown
- 2017-11-03 HU HUE17863293A patent/HUE052087T2/hu unknown
- 2017-11-03 CN CN201780067880.6A patent/CN109996441B/zh active Active
- 2017-11-03 CA CA3038720A patent/CA3038720A1/en active Pending
- 2017-11-03 KR KR1020217034468A patent/KR102492433B1/ko active Active
- 2017-11-03 PL PL22164751.4T patent/PL4082334T3/pl unknown
- 2017-11-03 PL PL20180508.2T patent/PL3766343T3/pl unknown
- 2017-11-03 HU HUE22164751A patent/HUE071595T2/hu unknown
- 2017-11-03 HR HRP20201403TT patent/HRP20201403T1/hr unknown
- 2017-11-03 KR KR1020237002504A patent/KR102658529B1/ko active Active
- 2017-11-03 IL IL308197A patent/IL308197A/en unknown
- 2017-11-03 ES ES20180508T patent/ES2915609T3/es active Active
- 2017-11-03 PL PL17863293T patent/PL3407709T3/pl unknown
- 2017-11-03 MX MX2019005256A patent/MX385857B/es unknown
- 2017-11-03 SG SG10201913483XA patent/SG10201913483XA/en unknown
- 2017-11-03 CN CN202210050898.8A patent/CN114369157A/zh active Pending
- 2017-11-03 RU RU2019112589A patent/RU2757665C2/ru active
- 2017-11-03 DK DK22164751.4T patent/DK4082334T3/da active
- 2017-11-03 DK DK20180508.2T patent/DK3766343T3/da active
- 2017-11-03 SM SM20250204T patent/SMT202500204T1/it unknown
- 2017-11-03 MA MA053935A patent/MA53935A/fr unknown
- 2017-11-03 HR HRP20250695TT patent/HRP20250695T1/hr unknown
- 2017-11-03 ES ES22164751T patent/ES3035365T3/es active Active
- 2017-11-03 RU RU2021129958A patent/RU2021129958A/ru unknown
- 2017-11-03 AU AU2017391167A patent/AU2017391167B2/en active Active
- 2017-11-03 PT PT221647514T patent/PT4082334T/pt unknown
- 2017-11-03 PT PT178632931T patent/PT3407709T/pt unknown
- 2017-11-03 FI FIEP22164751.4T patent/FI4082334T3/fi active
- 2017-11-03 SG SG11201903344XA patent/SG11201903344XA/en unknown
- 2017-11-03 EP EP20180508.2A patent/EP3766343B1/en active Active
- 2017-11-03 HR HRP20220888TT patent/HRP20220888T1/hr unknown
- 2017-11-03 EP EP25157740.9A patent/EP4567119A3/en active Pending
- 2017-11-03 EP EP17863293.1A patent/EP3407709B9/en active Active
- 2017-11-03 SI SI201731606T patent/SI4082334T1/sl unknown
- 2017-11-03 SI SI201730381T patent/SI3407709T1/sl unknown
- 2017-11-03 ES ES17863293T patent/ES2823305T3/es active Active
- 2017-11-03 LT LTEP22164751.4T patent/LT4082334T/lt unknown
- 2017-11-03 LT LTEP17863293.1T patent/LT3407709T/lt unknown
- 2017-11-03 RS RS20220669A patent/RS63390B1/sr unknown
- 2017-11-03 JP JP2019522647A patent/JP6884860B2/ja active Active
- 2017-11-03 HU HUE20180508A patent/HUE061980T2/hu unknown
- 2017-11-03 SM SM20200558T patent/SMT202000558T1/it unknown
- 2017-11-03 KR KR1020247012338A patent/KR20240055863A/ko active Pending
- 2017-11-03 SI SI201731147T patent/SI3766343T1/sl unknown
- 2017-11-03 RS RS20201205A patent/RS60886B1/sr unknown
- 2017-11-03 MA MA044091A patent/MA44091A/fr unknown
- 2017-11-03 DK DK17863293.1T patent/DK3407709T3/da active
- 2017-11-03 LT LTEP20180508.2T patent/LT3766343T/lt unknown
- 2017-11-03 SM SM20220259T patent/SMT202200259T1/it unknown
- 2017-11-03 BR BR112019008675A patent/BR112019008675A2/pt unknown
- 2017-11-03 RS RS20250535A patent/RS66884B1/sr unknown
- 2017-11-03 US US15/803,513 patent/US10820582B2/en active Active
- 2017-11-03 KR KR1020197015717A patent/KR102319069B1/ko active Active
-
2019
- 2019-05-03 MX MX2021010556A patent/MX2021010556A/es unknown
-
2020
- 2020-09-24 US US17/031,367 patent/US12433264B2/en active Active
- 2020-10-29 CY CY20201101022T patent/CY1123491T1/el unknown
-
2021
- 2021-03-08 JP JP2021036180A patent/JP2021090455A/ja not_active Withdrawn
-
2022
- 2022-07-07 JP JP2022109658A patent/JP7386292B2/ja active Active
- 2022-08-08 CY CY20221100540T patent/CY1125474T1/el unknown
-
2023
- 2023-02-17 JP JP2023023312A patent/JP2023053400A/ja not_active Withdrawn
-
2024
- 2024-01-31 AU AU2024200582A patent/AU2024200582B2/en active Active
-
2025
- 2025-08-18 JP JP2025135726A patent/JP2025166207A/ja active Pending
- 2025-09-05 US US19/320,545 patent/US20260068860A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008675A2 (pt) | roedor, célula isolada de roedor, e, métodos de produção de um roedor e de um anticorpo em um roedor. | |
| CY1125119T1 (el) | Διαγονιδιακο ζωο ποντικος που παραγει αντισωματα | |
| MX2024004496A (es) | Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos. | |
| BR112016005912A2 (pt) | sequência de ácido nucleico de cadeia leve de imunoglobulina recombinante, animal não humano geneticamente modificado, métodos para gerar um anticorpo e uma proteína de ligação e para produzir um animal não humano, célula ou tecido, vetor de alvejamento, proteína de ligação, e, ácido nucleico | |
| CY1122940T1 (el) | Μη ανθρωπινα ζωα που εχουν ενα εξανθρωπισμενο γονιδιο προγραμματισμενου κυτταρικου θανατου 1 | |
| CY1117606T1 (el) | Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα | |
| CY1121545T1 (el) | Ποντικοι που εκφραζουν περιορισμενο ρεπερτοριο ελαφριων αλυσιδων ανοσοσφαιρινης | |
| CY1122435T1 (el) | Ποντικοι με εξανθρωπισμενη καθολικη ελαφρια αλυσιδα | |
| NZ627977A (en) | Humanized rodents that express heavy chains containing vl domains | |
| BR112015019350A2 (pt) | Animal não humano, locus de imunoglobulina, e, métodos de fabricação de um animal não humano, para a obtenção de uma sequência de ácido nucleico e de fabricação de uma proteína de ligação ao antígeno | |
| BR112016011003A2 (pt) | animal roedor geneticamente modificado, célula tronco embrionária de camundongo, embrião de camundongo, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo | |
| BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
| SV2006002513A (es) | Anticuerpos anti-il-6, composiciones, metodos y usos ref. docket cen5094svnp | |
| WO2013144566A3 (en) | Animals expressing human lambda immunoglobulin light chain variable domain | |
| BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
| BR112016021572A2 (pt) | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação | |
| BR112016021679A2 (pt) | proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado. | |
| MX2015009594A (es) | Construcciones de anticuerpos para cdh19 y cd3. | |
| MX385330B (es) | Regulación transcripcional guiada por ácido ribonucleico. | |
| BR112016011004A2 (pt) | animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo | |
| NO20082783L (no) | Induserbare ekspresjonssystemer | |
| MX2024009271A (es) | Constructos de anticuerpos de acidos nucleicos optimizados. | |
| AR109451A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión | |
| AR098950A1 (es) | Anticuerpo contra bdca-2 humano | |
| CO2020005371A2 (es) | Anticuerpos anti-apoc3 y métodos de uso de estos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |